Is every CRO the same? Does experience in a specific trial phase really matter?
Choosing a CRO (Contract Research Organization) is one of the key decisions affecting the success of a clinical trial. In practice, sponsors often assume that most CROs handle all study phases and all types of projects to a similar extent. While many organizations do offer a broad service portfolio, industry reality shows that a CRO’s experience in a specific trial phase or project type has a direct impact on execution efficiency, data quality, and regulatory risk.
Clinical trials differ not only by therapeutic indication, but also by their level of operational complexity. Early-phase studies (Phase I–II) focus on safety, pharmacokinetics, and strict procedural control, requiring strong methodological expertise and precise data management. Phase III trials, by contrast, involve large-scale operations, multicenter recruitment, and extensive quality monitoring. Phase IV studies and Real World Evidence (RWE) projects require analytical capabilities, experience with real-world data, and expertise in observational research.
Not every CRO specializes equally across all of these areas. Some organizations focus on large global registration trials, while others have strong competencies in observational studies, medical devices, or academic projects. Differences also exist in biostatistical resources, regulatory experience, and knowledge of local legal requirements. As a result, selecting a CRO based only on price or general service scope may lead to a mismatch between the organization’s competencies and the actual needs of the project.
Experience in a specific trial phase primarily translates into a better ability to anticipate risks. A CRO that has repeatedly conducted similar studies can identify potential recruitment issues, common regulatory questions, or data management challenges at an earlier stage. This helps reduce the number of documentation revisions, shortens the start-up phase, and improves timeline predictability.
An equally important factor is familiarity with the specifics of different study types. Interventional drug trials, medical device studies, NIS projects, and RWE analyses all require different regulatory and operational approaches. A CRO with experience in a given project type is better equipped to tailor the study strategy, documentation package, and model of cooperation with research sites.
This does not mean that sponsors should only choose CROs that handle one specific type of study. The greatest value comes from organizations that offer broad competencies while also demonstrating real experience in projects most similar to the planned trial. The key question is therefore not “Does the CRO conduct all phases?” but rather “In which types of projects does it have proven experience and well-established processes?”
Biostat supports sponsors in conducting clinical trials, medical device studies, observational projects, and Real World Evidence initiatives by combining operational experience with strong biostatistical and regulatory expertise. This makes it possible to adapt the collaboration model to the specific trial phase and scientific objectives, rather than applying a one-size-fits-all approach to every project.
When selecting a CRO, it is therefore worth evaluating not only the declared service scope, but above all the organization’s experience in projects similar to the one being planned. Choosing the right partner from the very beginning significantly increases the chances of smooth study execution and obtaining reliable results.
